Ryan Wilson, who fell into a coma during a clinical drug trial in March, may lose parts of his fingers and toes. Wilson was the most seriously ill of the six men who suffered extensive swelling in their heads and bodies after being injected with TGN1412 to treat his rheumatoid arthritis.
Could Fall Off
Wilson could need to stay in the hospital six more months while his condition is monitored. His hands and feet have blackened, and parts of his fingers and toes have died and are likely to require amputation or fall off.
Intended to Treat Arthritis, Leukemia, MS
TGN1412 was created by German pharmaceutical company TeGenero, and the trials were administered by the medical research company Parexel. TGN1412 was intended to treat rheumatoid arthritis, leukemia and multiple sclerosis. Wilson participated in the paying trial to fund driving lessons and a trip.
Unconscious for Three Weeks
He suffered from heart, liver and kidney failure, as well as pneumonia and septicemia. He remained unconscious for nearly three weeks. The other five participants have all been released from hospital care.